,,iv  #aacth ,,congress  #ast ,session  
,h4 ,,res4 #afa  ,,in ,,the ,,house ,,of
 ,,representatives  ,april #ae1 #bjac   
,mr4 ,rogers of ,kentucky 7for himself1 
,mr4 ,keating1 ,mr4 ,wolf1 ,mr4 ,rahall1
 ,mr4 ,grimm1 ,mr4 ,lynch1 ,mr4         
,tierney1 and ,mr4 ,aderholt7 submitted 
the following resolution2 which was     
referred to the ,committee on ,energy   
and ,commerce  ,,resolution  ,expressing
 the sense of the ,house of             
,representatives that the ,food and     
,drug ,administration should encourage  
the use of abuse-deterrent formulations 
of drugs4  ,whereas when abuse-deterrent
 formulations of a drug have been       
developed1 approved1 and recognized as  
effective by the ,food and ,drug        
,administration1 the approval and       
marketing of generic versions that do   
not have abuse-deterrent features are   
likely to prevent achievement of the    
public health purposes of the efforts to
 develop such abuse-deterrent           
formulations2 ,whereas the ,office of   

,national ,drug ,control ,policy and the
 ,food and ,drug ,administration have   
for many years strongly encouraged      
manufacturers of opioid drug products to
 develop abuse-deterrent formulations   
designed to prevent or discourage the   
abuse or misuse of those products2      
,whereas in response1 several opioid    
drug manufacturers have developed       
abuse-deterrent formulations2 ,whereas  
helping to reduce the level of abuse of 
opioid drug products is dependent on the
 widespread adoption of new technologies
 and approaches to the safer formulation
 of these drugs2 ,whereas the           
,commissioner of ,food and ,drugs has   
acknowledged that the ,food and ,drug   
,administration has the authority under 
current law to require generic versions 
of products that have been formulated or
 reformulated with abuse-deterrent      
features to have comparable features2   
and ,whereas fourteen ,members of       
,congress in a bipartisan coalition have
 cosponsored the ,stop ,tampering with  

,prescription ,pills 7,,stopp7 ,act1    
which would similarly promote           
abuse-deterrent technologies in         
addictive painkillers3 ,now1 therefore1 
be it  ,that it is the sense of the     
,house of ,representatives that the     
,food and ,drug ,administration should  
exercise its acknowledged authority to--
  7#a7 refuse to approve generic        
versions of non-abuse-deterrent opioid  
products that have been replaced in the 
market with abuse-deterrent             
formulations2 and  7#b7 require generic 
versions of abuse-deterrent opioid      
products to be formulated with          
comparable abuse-deterrent features4